

Title (en)  
CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS.

Title (de)  
CYCLOALKYL SUBSTITUIERTE GLUTARAMIDE ALS ANTIHYPERTENSIVE WIRKSTOFFE.

Title (fr)  
AGENTS ANTIHYPERTENSIFS AU GLUTARAMIDE SUBSTITUE PAR CYCLOALKYLE.

Publication  
**EP 0594588 A1 19940504 (EN)**

Application  
**EP 91903839 A 19910214**

Priority  
• EP 9100296 W 19910214  
• GB 9004260 A 19900226

Abstract (en)  
[origin: WO9113054A1] Compounds of formula (I), wherein A completes a 5 or 6 membered carbocyclic ring which may be saturated or monounsaturated; Y is an alkylene group of from 1 to 9 carbon atoms; R<1> is H or (C1-C4)alkyl; R and R<4> are H, (C1-C6)alkyl, (C3-C7)cycloalkyl, benzyl, or an alternative biolabile ester-forming group; R<2> is defined to include a range of substituent groups including (C1-C6)alkoxy, (C1-C4)alkoxy-(C1-C6)alkoxy and various substituted-alkyl, amino, substituted amino, aryl and heterocyclyl substituents linked directly or by O, S(O)n, NR<6>, CO or CONR<6> wherein R<6> is H, (C1-C4)alkyl or aryl(C1-C4)alkyl and n is 0, 1 or 2; R<3> is a group of formula (II), wherein R<13> is H, halo, 4-OH, 4-(C1-C6 alkoxy), 4-(C3-C7 cycloalkoxy), 4-(C2-C6 alkenyloxy), 4-[(C1-C6 alkoxy)carbonyloxy], 4-[(C3-C7 cycloalkyloxy)carbonyloxy], or 3-(C1-C4 alkyl)SO<sub>2</sub>NH-; and R<14> is H, (C1-C4)alkyl, (C1-C4)alkoxy, (C2-C6)alkanoyl or halo; or R<3> is a group of formulae (III) or (IV), wherein said groups may optionally be substituted in the fused benzene ring by (C1-C4)alkyl, (C1-C4)alkoxy, OH, halo or CF<sub>3</sub>; or are atriopeptidase inhibitors or utility in the treatment of hypertension and heart failure.

Abstract (fr)  
On décrit des composés de formule (I), où A complète un anneau carbocyclique à 5 ou 6 branches qui peut être saturé ou mono non saturé; Y est un groupe alkylène ayant entre 1 et 9 atomes de carbone; R<sub>1</sub> est H ou (C1-C4)alkyle; R et R<sub>4</sub> sont H, (C1-C6)alkyle, (C3-C7)cycloalkyle, benzyle, ou un autre groupe biolabile formant des esters; R<sub>2</sub> est défini pour inclure une série de groupes substituants comprenant (C1-C6)alkoxy, (C1-C4)alkoxy-(C1-C6)alkoxy et divers substituants à substitution d'alkyle, amino, à substitution d'amino, aryle et hétérocyclyle liés directement ou par O, S(O)<sub>n</sub>, NR<sub>6</sub>, CO ou CONR<sub>6</sub>, où R<sub>6</sub> est H, (C1-C4)alkyle ou aryle(C1-C4)alkyle et n est 0, 1 ou 2; R<sub>3</sub> est un groupe de la formule (II), où R<sub>13</sub> est H, halo, 4-OH, 4-(C1-C6alkoxy), 4-(C3-C7 cycloalkoxy), 4-(C2-C6 alkényloxy), 4-[(C1-C6alkoxy)carbonyloxy], 4-[(C3-C7 cycloalkyloxy)carbonyloxy], ou 3-(C1-C4 alkyl)SO<sub>2</sub>NH-; et R<sub>14</sub> est H, (C1-C4)alkyle, (C1-C4alkoxy, (C2-C6alkanoyl ou halo; ou R<sub>3</sub> est un groupe de formule (III) où lesdits groupes peuvent être substitués facultativement dans l'anneau de benzène fusionné par (C1-C4)alkyle, (C1-C4)alkoxy, OH, halo ou CF<sub>3</sub>; ou ils sont des inhibiteurs d'atriopeptidase utiles dans le traitement de l'hypertension et d'insuffisance cardiaque.

IPC 1-7  
**C07C 237/24**

IPC 8 full level  
**A61K 31/195** (2006.01); **A61K 31/215** (2006.01); **A61K 31/35** (2006.01); **A61K 31/351** (2006.01); **A61K 31/40** (2006.01); **A61K 31/403** (2006.01); **A61K 31/404** (2006.01); **A61K 31/415** (2006.01); **A61K 31/445** (2006.01); **A61P 9/04** (2006.01); **A61P 9/12** (2006.01); **A61P 43/00** (2006.01); **C07C 233/63** (2006.01); **C07C 235/40** (2006.01); **C07C 237/22** (2006.01); **C07C 237/24** (2006.01); **C07C 237/36** (2006.01); **C07C 237/42** (2006.01); **C07C 247/12** (2006.01); **C07C 271/22** (2006.01); **C07C 271/66** (2006.01); **C07C 273/18** (2006.01); **C07C 311/06** (2006.01); **C07C 317/44** (2006.01); **C07C 317/48** (2006.01); **C07C 323/52** (2006.01); **C07C 323/60** (2006.01); **C07D 209/14** (2006.01); **C07D 211/46** (2006.01); **C07D 211/58** (2006.01); **C07D 211/74** (2006.01); **C07D 231/56** (2006.01); **C07D 233/60** (2006.01); **C07D 295/14** (2006.01); **C07D 295/145** (2006.01); **C07D 309/12** (2006.01); **C07D 521/00** (2006.01); **C07C 275/22** (2006.01)

CPC (source: EP)  
**A61P 9/04** (2017.12); **A61P 9/12** (2017.12); **A61P 43/00** (2017.12); **C07C 233/63** (2013.01); **C07C 235/40** (2013.01); **C07C 237/24** (2013.01); **C07C 237/36** (2013.01); **C07C 247/12** (2013.01); **C07C 271/22** (2013.01); **C07C 271/66** (2013.01); **C07C 273/1854** (2013.01); **C07C 317/44** (2013.01); **C07C 317/48** (2013.01); **C07C 323/60** (2013.01); **C07D 211/46** (2013.01); **C07D 211/58** (2013.01); **C07D 211/74** (2013.01); **C07D 231/12** (2013.01); **C07D 233/56** (2013.01); **C07D 249/08** (2013.01); **C07D 295/145** (2013.01); **C07D 309/12** (2013.01); **C07C 2601/08** (2017.04)

Citation (search report)  
See references of WO 9113054A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

DOCDB simple family (publication)  
**WO 9113054 A1 19910905**; CA 2073450 A1 19910827; EP 0594588 A1 19940504; FI 923780 A0 19920821; FI 923780 A 19920821; GB 9004260 D0 19900418; IE 910615 A1 19910828; JP H05504146 A 19930701; PT 96863 A 19911129

DOCDB simple family (application)  
**EP 9100296 W 19910214**; CA 2073450 A 19910214; EP 91903839 A 19910214; FI 923780 A 19920821; GB 9004260 A 19900226; IE 61591 A 19910225; JP 50397391 A 19910214; PT 9686391 A 19910225